title: Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells.
abstract: Prostate-specific membrane antigen is a type II membrane protein with folate hydrolase activity produced by prostatic epithelium. It has been demonstrated that prostate-specific membrane antigen over-expression may be correlated with prostate cancer, particularly in advanced cancer. The aim of the current study was to explore the possibility of prostate-specific membrane antigen as a therapeutic target for the treatment of prostate cancer. To address this problem, lentivirus-mediated small interfering RNA was employed to reduce endogenous prostate-specific membrane antigen expression in prostate cancer cell lines—LNCaP and DU-145. Then, the tumorigenesis, migration ability and invasiveness of prostate-specific membrane antigen-reduced prostate cancer cell lines were also examined. The prostate-specific membrane antigen expression in LNCaP and DU-145 cells was persistently and markedly reduced by lentivirus-mediated RNA interference. Down-regulation of prostate-specific membrane antigen expression significantly suppressed the growth rates of LNCaP and DU-145 cells. Moreover, the specific down-regulation arrested cells in G0/G1 phase of cell cycle. Furthermore, we also observed that the silence of prostate-specific membrane antigen could decrease the migration ability and the invasiveness of LNCaP and DU-145 cells. Our investigation demonstrated that lentivirus-mediated RNA interference silencing targeting prostate-specific membrane antigen might reduce the proliferation, and induce potent antitumor activity of LNCaP and DU-145 cells. Prostate-specific membrane antigen has considerable potential as a new therapeutic target for the treatment of prostate cancer.
authors.affiliation: Department of Urology, The Second Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
authors.forename: Zhenghui
authors.initials: Z
authors.lastname: Guo
authors.forename: Hai
authors.initials: H
authors.lastname: Huang
authors.forename: Lexiang
authors.initials: L
authors.lastname: Zeng
authors.forename: Tao
authors.initials: T
authors.lastname: Du
authors.forename: Kewei
authors.initials: K
authors.lastname: Xu
authors.forename: Tianxin
authors.initials: T
authors.lastname: Lin
authors.forename: Chun
authors.initials: C
authors.lastname: Jiang
authors.forename: Wen
authors.initials: W
authors.lastname: Dong
authors.forename: Yi
authors.initials: Y
authors.lastname: Cao
authors.forename: Jieqing
authors.initials: J
authors.lastname: Chen
authors.forename: WeiDe
authors.initials: W
authors.lastname: Zhong
authors.forename: Jian
authors.initials: J
authors.lastname: Huang
mesh_terms: D015153:Blotting, Western; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics*; D049109:Cell Proliferation; D002469:Cell Separation; D005434:Flow Cytometry; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D016086:Lentivirus / Q000235:genetics; D008297:Male; D009361:Neoplasm Invasiveness / Q000235:genetics*; D017430:Prostate-Specific Antigen / Q000037:antagonists & inhibitors* / Q000235:genetics; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D034622:RNA Interference; D034741:RNA, Small Interfering; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D034741:RNA, Small Interfering; D017430:Prostate-Specific Antigen
references.citation: Cancer Invest. 1989;7(2):179-92
references.pmid: 2676086
references.citation: Gene Ther. 2005 Jul;12(14):1089-98
references.pmid: 16003340
references.citation: Semin Urol Oncol. 1998 Feb;16(1):2-12
references.pmid: 9508077
references.citation: Cancer Res. 1994 Apr 1;54(7):1807-11
references.pmid: 7511053
references.citation: Prostate. 2006 Nov 1;66(15):1641-52
references.pmid: 16927306
references.citation: Nature. 2002 Jul 11;418(6894):244-51
references.pmid: 12110901
references.citation: N Engl J Med. 2003 Jul 24;349(4):366-81
references.pmid: 12878745
references.citation: Nat Protoc. 2006;1(1):234-40
references.pmid: 17406238
references.citation: Leuk Res. 2009 Aug;33(8):1114-9
references.pmid: 19036441
references.citation: J Transl Med. 2008 Oct 04;6:55
references.pmid: 18834541
references.citation: Urology. 1998 Oct;52(4):637-40
references.pmid: 9763084
references.citation: Hematology Am Soc Hematol Educ Program. 2007;:473-81
references.pmid: 18024667
references.citation: Curr Hematol Rep. 2005 Jul;4(4):300-4
references.pmid: 16009045
references.citation: Prostate Cancer Prostatic Dis. 2002;5(1):36-46
references.pmid: 15195129
references.citation: Br J Cancer. 2006 Nov 6;95(9):1186-94
references.pmid: 17077805
references.citation: Mod Pathol. 2008 May;21 Suppl 2:S44-55
references.pmid: 18437173
references.citation: J Urol. 1998 Dec;160(6 Pt 2):2396-401
references.pmid: 9817391
references.citation: Neoplasia. 2006 Nov;8(11):917-24
references.pmid: 17132223
references.citation: Cancer Res. 1997 Jun 15;57(12):2321-4
references.pmid: 9192800
references.citation: Hum Pathol. 2007 May;38(5):696-701
references.pmid: 17320151
references.citation: Am J Physiol Cell Physiol. 2005 May;288(5):C975-81
references.pmid: 15840561
references.citation: BMJ. 2008 Mar 15;336(7644):610-2
references.pmid: 18340076
references.citation: Trends Biotechnol. 2003 Mar;21(3):117-22
references.pmid: 12628368
references.citation: J Pharm Pharmacol. 2008 Apr;60(4):405-13
references.pmid: 18380911
references.citation: Prostate. 2004 Feb 1;58(2):200-10
references.pmid: 14716746
references.citation: Clin Cancer Res. 2003 Dec 15;9(17):6357-62
references.pmid: 14695135
references.citation: Urol Oncol. 2009 Sep-Oct;27(5):539-47
references.pmid: 18639471
references.citation: Jpn J Clin Oncol. 2003 Jan;33(1):1-5
references.pmid: 12604715
references.citation: Urology. 2001 Jun;57(6):1179-83
references.pmid: 11377343